prostate%20cancer
PROSTATE CANCER

Prostate cancer is the cancer that occurs in the male's prostate.

It is the most common cancer in men >50 years of age.

Signs and symptoms include weak urinary stream, polyuria, nocturia, hematuria, erectile dysfunction, pelvic pain, back pain, chest pain, lower extremity weakness or numbness and loss of bowel or bladder control.

Differential Diagnosis

  • Benign prostatic hypertrophy
  • Sarcoma
  • Small cell carcinoma
  • Transitional cell carcinomas
  • Neuroendocrine tumors
Editor's Recommendations
Most Read Articles
24 Sep 2017
Women with very low levels of serum testosterone may have an increased likelihood of stress and mixed incontinence, a recent study suggests.
01 Nov 2017
Xerostomia and salivary gland hypofunction appear to be common side effects of elderly medication, particularly those for urinary incontinence, according to a recent study.
29 Oct 2017
Older women with urinary incontinence symptoms exhibit a significant decline in standing balance, which may be associated with coinciding development of sarcopaenia, according to the secondary analysis of the Health, Aging and Body Composition Study.
Dr Jaime Songco, 31 Oct 2017

Erectile dysfunction (ED) is a common condition defined as the persistent inability to achieve or maintain an erection sufficient for satisfactory sexual performance.1 It is one of the most common complaints in men’s sexual medicine, affecting both physical and psychosocial health and having a significant impact on the patient and partner’s quality of life.1 Moreover, ED is commonly associated with other comorbid conditions, including hypertension, dyslipidaemia and diabetes mellitus.1

Evaluation of ED should include a detailed medical and sexual history of the patient. 1 A discussion of the patient and partner’s preference and treatment goals is essential to better tailor treatment and improve patient satisfaction and adherence to treatment.2 Lifestyle modification and management of risk factors should precede pharmacotherapy, while first-line treatment with oral phosphodiesterase type 5 inhibitors (PDE5i) is well established for the management of patients with ED.1